Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma Inc. is repositioning itself as an autoimmune-focused biopharmaceutical company centered on telitacicept, a BAFF/APRIL‑targeting fusion protein in-licensed from RemeGen in June 2025. Telitacicept is already approved in China for SLE, RA and gMG, with additional Biologics License Applications pending for Sjögren’s disease and IgA nephropathy.
The company now leads global Phase 3 trials in generalized myasthenia gravis and Sjögren’s disease to support potential approvals in the United States, Europe and Japan, leveraging extensive Chinese Phase 3 data showing durable efficacy and a favorable safety profile. Earlier oncology and cell therapy programs, including trem-cel and VCAR33, have been discontinued and related intellectual property sold.
Under the telitacicept license, Vor paid a $125 million upfront (including a warrant for 16,000,000 shares) and owes up to $330 million in regulatory and $3.775 billion in sales milestones, plus tiered royalties. In March 2026 it agreed to a $75.0 million private placement of 5,338,078 shares at $14.05 per share with TCGX affiliates, and has granted registration rights for resale. A 1‑for‑20 reverse stock split was effected in September 2025, and 48,847,504 common shares were outstanding as of March 23, 2026.
Vor Biopharma Inc. entered into a securities purchase agreement with entities affiliated with TCGX for a private placement of 5,338,078 common shares at $14.05 per share, for gross proceeds of about $75.0 million. The closing is expected on or about March 30, 2026, subject to customary conditions.
After closing, Vor expects to have 54,185,582 common shares outstanding. The company plans to use the net proceeds to advance its clinical pipeline, including telitacicept programs, and for general corporate purposes. No placement agent was used. Vor also granted investors registration rights and will file a Form S-3 to register the resale of the new shares.
Vor Biopharma Inc. attracted a larger disclosed stake from RA Capital-affiliated investors through a change in warrant terms. RA Capital Management, its healthcare fund, and managers Peter Kolchinsky and Rajeev Shah now report beneficial ownership of 9,023,068 shares of common stock, representing 19.9% of the class based on 41,519,840 shares outstanding as of January 26, 2026. The increase stems from a March 12, 2026 notice raising the Pre-Funded Warrants’ maximum ownership percentage from 9.99% to 19.99%, which caused an additional 3,611,297 warrant shares to be counted as beneficially owned, effective March 13, 2026. The filing also notes ownership through common shares, common stock warrants, and stock options held for RA Capital’s benefit.
Vor Biopharma Inc. received an amended Schedule 13G from Verve Capital Limited, a Samoa-organized entity, reporting a significant passive stake. Verve Capital beneficially owns 4,297,464 shares of common stock through pre-funded warrants, subject to a 9.99% ownership blocker.
The 9.99% beneficial ownership is calculated using 38,720,196 shares of common stock outstanding as of December 18, 2025, plus 4,297,464 shares issuable upon exercise of the pre-funded warrants. Verve Capital certifies the holding is not for the purpose of changing or influencing control of Vor Biopharma.
Vor Biopharma Inc. large holder disclosure: A group of Venrock Healthcare Capital entities and individuals Nimish Shah and Bong Koh report beneficial ownership of 2,216,075 shares of Vor Biopharma common stock as of December 31, 2025, representing 9.99% of the company.
The position includes common shares and Pre-Funded Warrants held across VHCP III, VHCP Co-Investment III and VHCP EG, all subject to a 9.99% beneficial ownership blocker that limits warrant exercise. The percentage is calculated using 21,910,630 shares outstanding as of November 19, 2025 plus 272,309 shares issuable upon warrant exercise.
Vor Biopharma Inc. received an updated ownership filing from Great Point Partners and related individuals. The group reports beneficial ownership of 1,370,107 shares of Vor Biopharma common stock, representing 3.30% of the outstanding shares.
Great Point Partners, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl report shared voting and shared dispositive power over all 1,370,107 shares, with no sole voting or dispositive power. The percentage is based on 41,519,840 shares outstanding as reported in Vor Biopharma’s Form S-3 on January 29, 2026. The filers certify the shares are held on a passive basis and represent ownership of 5 percent or less of the class.
VOR Biopharma Inc. received an updated ownership report from Paradigm BioCapital entities and related persons on an amended Schedule 13G. Paradigm BioCapital Advisors LP, its general partner, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. together report beneficial ownership of 1,750,000 shares of VOR Biopharma common stock.
This stake represents 4.5% of the outstanding common stock, based on 38,720,196 sharesDecember 31, 2025. The Paradigm BioCapital International Fund Ltd. itself directly holds 1,546,061 shares, or 4.0% of the class. The reporting group certifies that the securities were not acquired to change or influence control of VOR Biopharma.
Qiming-affiliated investment entities filed an amended Schedule 13G reporting their passive ownership in Vor Biopharma Inc.’s common stock. Qiming Venture Partners VIII-HC, L.P. and Qiming GP VIII-HC, LLC each report beneficial ownership of 1,089,767 shares, representing 2.8% of the common stock outstanding as of December 31, 2025. Qiming Venture Partners VIII Investments, LLC and Qiming GP VIII, LLC each report beneficial ownership of 910,172 shares, representing 2.4% of the same share class. All reporting persons certify the holdings were not acquired to change or influence control of Vor Biopharma.
Vor Biopharma Inc. has filed a resale prospectus covering up to 13,876,032 shares of common stock previously issued in a December 18, 2025 private placement. These shares were sold to accredited investors at $10.81 per share for gross proceeds of $150 million.
The company is a clinical-stage biopharmaceutical business developing telitacicept for autoimmune diseases, including a global Phase 3 trial in generalized myasthenia gravis. Only the selling stockholders will receive proceeds from any share sales; Vor will cover registration costs but not selling expenses. The filing warns that large resales could pressure the stock price and notes that prior audited financial statements included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
FMR LLC filed an amended Schedule 13G stating beneficial ownership of 2,526,170 shares of Vor Biopharma Inc. common stock, representing 6.5% of the class as of 12/31/2025. Abigail P. Johnson is also reported as beneficial owner with sole dispositive power over the same shares.
The filing notes that one or more other persons, including Select Biotechnology Portfolio with 2,522,625 shares (6.5% of outstanding common stock as of 12/31/2025), have rights to receive dividends or sale proceeds. The securities are certified as held in the ordinary course of business without the purpose of influencing control.